Literature DB >> 15212979

Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs.

Hiroshi Nagabukuro1, Satoshi Okanishi, Takayuki Doi.   

Abstract

In the present study, we investigated the effects of cholinomimetic drugs on the urodynamic characteristics in anesthetized guinea pigs. 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802), a novel acetylcholinesterase inhibitor, (0.003-0.03 mg/kg, i.v.) increased the voided volume and the maximum flow rate without affecting either the intravesical pressure or the bladder compliance. Distigmine (0.03-0.3 mg/kg, i.v.) and neostigmine (0.01-0.1 mg/kg, i.v.), both carbamate acetylcholinesterase inhibitors, while not increasing the maximum flow rate, increased the intravesical pressure at the maximum flow rate. They also decreased the bladder compliance. Bethanechol (0.1-1 mg/kg, i.v.), a muscarinic receptor agonist, decreased the voided volume and the bladder compliance but did not affect the maximum flow rate. TAK-802 did not affect the intraurethral pressure at doses of up to 0.03 mg/kg in anesthetized guinea pigs. Distigmine increased the intraurethral pressure when administered at the dose of 0.3 mg/kg, and the effect was completely abolished by pretreatment with d-tubocurarine. These results suggest that TAK-802 reinforces the bladder-voiding functions by increasing the bladder contractility without decreasing the storage function. On the other hand, carbamate acetylcholinesterase inhibitors not only deteriorate the voiding function by inducing contraction of the external urethral sphincter muscle, resulting in increasing the urethral resistance, but also cause deterioration of the storage function. Bethanechol obviously decreased the bladder capacity, possibly due to a direct contractile effect on the detrusor smooth muscle. TAK-802 may therefore be a more useful drug than either carbamate acetylcholinesterase inhibitors or muscarinic receptor agonists in the treatment of voiding dysfunction associated with impaired detrusor contractility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212979     DOI: 10.1016/j.ejphar.2004.05.007

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex.

Authors:  Morihiro Fujimura; Naoki Izumimoto; Sayoko Kanie; Ryosuke Kobayashi; Satoru Yoshikawa; Shinobu Momen; Mikito Hirakata; Toshikazu Komagata; Satoshi Okanishi; Masashi Iwata; Tadatoshi Hashimoto; Takayuki Doi; Naoki Yoshimura; Koji Kawai
Journal:  Int Urol Nephrol       Date:  2017-01-16       Impact factor: 2.370

2.  Effects of anesthetics on cystometric parameters in female rats.

Authors:  Cuneyd Ozkurkcugil; Levend Ozkan
Journal:  Int Urol Nephrol       Date:  2010-05-13       Impact factor: 2.370

3.  Excitatory effect of acotiamide on rat and human bladder: Implications for underactive bladder treatment.

Authors:  Nishant Singh; Shinsuke Mizoguchi; Takahisa Suzuki; Irina Zabbarova; Youko Ikeda; Anthony Kanai; Christopher Chermansky; Naoki Yoshimura; Pradeep Tyagi
Journal:  Life Sci       Date:  2020-08-03       Impact factor: 5.037

4.  Marked hydronephrosis and hydroureter after distigmine therapy in an adult male patient with paraplegia due to spinal cord injury: a case report.

Authors:  Subramanian Vaidyanathan; Paul Mansour; Bakul M Soni; Peter L Hughes; Gurpreet Singh; Tun Oo
Journal:  Cases J       Date:  2009-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.